RCT 70 hospitalized severe COVID-19 patients in Iran, showing lower mortality and improved clinical markers with treatment combining vitamins A, B1–B3, B5, B6, B9, C, D, K, and magnesium, potassium, phosphorus, sulfur, manganese, calcium, iron, boron, copper, zinc, omega-3, omega-6, and omega-9. The median age was lower in the treatment group 49 (29–77) vs. 55 (29–81).
risk of death, 60.9% lower, RR 0.39, p = 0.002, treatment 9 of 35 (25.7%), control 23 of 35 (65.7%), NNT 2.5.
hospitalization time, 28.2% lower, relative time 0.72, p = 0.001, treatment 35, control 35.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta
combination of several treatments showing efficacy in other trials.
Mosadegh et al., 19 Sep 2022, Single Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, median age 48.7, 4 authors, this trial uses multiple treatments in the treatment arm (combined with vitamins A, B1–B3, B5, B6, B9, C, D, K, and magnesium, potassium, phosphorus, sulfur, manganese, calcium, iron, boron, copper, zinc, omega-3, omega-6, omega-9) - results of individual treatments may vary, trial IRCT20200426047206N1